Hybio Pharmaceutical (300199.SZ) signs agreement for joint development of peptide-based innovative drugs.

Hybio Pharmaceutical (300199.SZ) announced that on May 9, 2025, the company held the fourth meeting of the sixth board of directors and approved the "Proposal on Signing". The company agreed to sign a joint development agreement with Shenzhen Carbon Cloud Smart Peptide Pharmaceutical Technology Co., Ltd. (referred to as "Carbon Cloud Smart Peptide") for the innovative peptide drug of GLP-1R/GIPR/GCGR triple agonist. Based on the previous collaboration results, in order to further promote the project progress, both parties intend to deepen their cooperation and jointly develop innovative peptide drugs. The dosage forms of peptide drugs include but are not limited to injections, oral formulations, etc., and will be used in the treatment of metabolic diseases such as weight control.